<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1416</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"/><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>DO STATINS HAVE POTENTIAL AS ANTI OSTEOPOROTIC DRUGS AND CAN THEY BE USED FOR PREVENTION OR TARGETING OSTEOPOROSIS: A REVIEW&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rath</surname><given-names>Karmajeet</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mohanty</surname><given-names>Biswa Bhusan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Sanjay</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nayak</surname><given-names>Pramila</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sahoo</surname><given-names>Jagannath</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>28</day><month>02</month><year>2013</year></pub-date><volume/><issue/><fpage>73</fpage><lpage>81</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Inhibitors of HMG-CoA reductase enzymes, which are statins, are well known and much prescribed drugs for lowering of cholesterol and used for dyslipidemia. But, they have also been shown across various studies to stimulate bone formation. In bone cells, these inhibitors have been known to increase the gene expression of bone morphogenetic protein-2, thereby helping in osteoblastic differentiation, with some effects also on osteoclastic inhibition. The findings that statins can increase bone formation and thereby mass of bone, can be helpful in preventing bone fractures and improving osteoporosis, which is a condition of marked bone loss. Hence, it is reviewed herein that HMG-CoA reductase inhibitors can be a great way, probably a futuristic drug for osteoporotic treatment and prevention. Keywords: HMG-CoA reductase inhibitors, osteoporosis&#13;
</p></abstract><kwd-group><kwd>HMG-CoA reductase inhibitors</kwd><kwd> osteoporosis</kwd><kwd> osteoblasts</kwd><kwd> statins</kwd><kwd> bone metabolism</kwd><kwd> fracture</kwd></kwd-group></article-meta></front></article>
